AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...

These days, with its revenue booming and a market cap swelling to twice the size of | Eli Lilly said it will spend $3 billion ...

Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...

AstraZeneca has refuted allegations its staff “refuse to cooperate and respect” the U.K. marketing code. | AstraZeneca has ...

Last week, the immuno-oncology specialist revealed that part of the new setup will include CDMO services, as it will produce ...

Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...

Amid a flurry of manufacturing activity in the state this year, Amgen is the latest drugmaker to bolster its production ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...

Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down ...

Merus’ week keeps getting better. Days after securing a long-awaited commercialization partner for its zenocutuzumab, the ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...